Enclomiphene citrate is the trans isomer of clomiphene, a non-steroidal selective estrogen receptor modulator that blocks estrogen feedback at the pituitary so.
Amounts reported for Enclomiphene Citrate are listed under Reported protocols, each with its source and study kind. No amount ladder is inferred from them. This is educational source context, not a protocol or recommendation.
Enter a target amount only from your own reviewed source. The calculator can convert it into concentration, volume and device markings, but it will not infer an amount from product availability or another compound.
Only mcg or mg amounts are retained. The calculator derives mL, syringe units or pen clicks from the current vial strength, water volume and device.
Human study rows are described per source under Reported protocols; they belong to their trial populations and are not a general amount.
Verify the exact compound, formulation and amount against the product label or certificate before calculation.
Follow the product label, certificate and validated laboratory SOP; no universal storage assumption is applied here.
Label concentration and preparation date, use sterile technique where applicable, and follow a validated stability protocol.
What published studies and recent community write-ups report about amounts, timing and course length. 3 clinical and 2 community-reported rows, each linked to its source. These are descriptions of what others report, not instructions, and nothing here is medical advice.
| Context | Dose | Frequency | Route | Course | Source |
|---|---|---|---|---|---|
| Clinical3 rows | |||||
| Phase 2 dose-ranging pharmacodynamic and pharmacokinetic study48 men with secondary hypogonadism (total testosterone below 350 ng/dL, LH below 12 IU/L); 44 completed per protocol | 6.25 mg, 12.5 mg or 25 mg (versus 5 g of transdermal testosterone gel) | Once daily, taken between 7:00 and 10:00 in the morning | Oral capsule | 6 weeks of continuous daily dosing, with 24-hour hormone profiles on day 1 and day 42Effects on LH and testosterone persisted for at least a week after stopping | BJU International (PubMed)2013 |
| After 6 weeks, morning total testosterone averaged 604 ng/dL on 25 mg versus 500 ng/dL on testosterone gel, and all three doses raised testosterone into the normal range while pushing LH and FSH above normal; the gel suppressed both gonadotropins. The authors judged 12.5 mg and 25 mg the useful doses, with 6.25 mg giving a less reliable response. The study was sponsored and partly authored by the drug's developer. | |||||
| Two parallel Phase 3 trials versus testosterone gel (ZA-304 and ZA-305)Overweight men aged 18-60 with secondary hypogonadism (total testosterone 300 ng/dL or less, LH below 9.4 IU/L) | Two daily oral doses, reported by secondary sources as the program's 12.5 mg and 25 mg capsules | Once daily | Oral, double-dummy against AndroGel 1.62% | 16 weeksNone described | BJU International (PubMed)2016 |
| Both enclomiphene doses raised total testosterone, LH and FSH and kept sperm concentration in the normal range, while testosterone gel raised testosterone but lowered LH and FSH and markedly reduced sperm counts. The published abstract names two doses without stating them; the 12.5 mg and 25 mg figures come from the developer's earlier trials and later reviews. An earlier Phase 2 trial (NCT01270841) from the same program reported the same pattern of preserved sperm counts. | |||||
| British Society of Sexual Medicine position statementMen with testosterone deficiency, especially those who want to preserve fertility or cannot use injections or gels | Begin at 6.25 mg; increase up to 25 mg; may be raised to 50 mg if the clinical or biochemical response is inadequate | Once daily, increasing weekly as tolerated | Oral | Not fixed; the statement notes a retrospective series with a median 8.9 months of treatmentNot described | World Journal of Men's Health2026 |
| The 2026 statement recommends specialist-only, research-framework use because the drug is unlicensed in the UK and the evidence comes from small, short studies. It summarizes a retrospective comparison in which 30% of enclomiphene patients took 12.5 mg daily and 70% took 25 mg daily against clomiphene 50 mg every other day, and lists headache (1.6%), hot flushes (1.1%), nausea (1.0%), muscle spasms (0.9%) and dizziness (0.7%) as the reported undesirable effects. | |||||
| Community-reported2 rows | |||||
| Evidence and risk summary for off-label use | 12.5 mg and 25 mg are the trial doses; amounts above 25 mg a day have not been tested in controlled trials | Once daily | Oral, compounded | Not fixed; the page describes follow-up labs at roughly 4-6 weeks and then every 3-6 monthsNot described | Community resource2025 |
| This 2025 page is a consumer-facing evidence summary rather than a protocol. It states that no FDA-approved prescribing information exists, that the drug is available only off-label through compounding, and that any starting dose or titration should come from a prescriber who has reviewed testosterone, LH, FSH, estradiol and blood count results. | |||||
| Research-vendor listing (format only) | 12.5 mg capsules; third-party assays of recent lots measured 11.92-14.75 mg per capsule | Not stated | Oral capsules; the vendor also lists a liquid form; sold for laboratory research only | Not statedNot stated | Community resource2026 |
| This is a vendor page, not a protocol. The capsule strength matches the lower trial dose, and the published certificates show lot-to-lot content ranging from about 5% under to 18% over label, which matters for anyone comparing a research capsule with a pharmacy-compounded one. The page gives no dosing information. | |||||
The BSSM statement describes starting at 6.25 mg once daily by mouth, the lowest dose tested in the Phase 2 dose-ranging study.
The dose is raised weekly as tolerated to 25 mg daily, with a further increase to 50 mg daily only if the clinical or biochemical response is inadequate. The 50 mg step has no controlled-trial data behind it.
The trials themselves used fixed daily doses rather than titration: 6 weeks at 6.25, 12.5 or 25 mg in the Phase 2 study and 16 weeks in the Phase 3 trials. Testosterone rose within 2 weeks and stayed elevated for at least a week after the last dose.
Plus 2 community resources (dosing guides, forum threads and vendor write-ups), reported above but not linked.
Enclomiphene citrate is the trans isomer of clomiphene, a non-steroidal selective estrogen receptor modulator that blocks estrogen feedback at the pituitary so that LH and FSH rise and the testes make more of their own testosterone. Repros Therapeutics developed it under the name Androxal for secondary hypogonadism in overweight men who wanted to keep their fertility, ran Phase 2 and Phase 3 trials at 12.5 mg and 25 mg a day against testosterone gel, and received an FDA Complete Response Letter in December 2015 asking for new Phase 3 studies; the European application was not approved either and development was discontinued in 2021. It is an oral small molecule rather than a peptide, so there is no vial or reconstitution involved, and it reaches patients today only as a compounded prescription or a research-grade product.
These themes describe recurring questions in published research. They are not claims of effectiveness or recommendations for use.
Hormonal, reproductive and sexual-function research.
After 6 weeks, morning total testosterone averaged 604 ng/dL on 25 mg versus 500 ng/dL on testosterone gel, and all three doses raised testosterone into the normal range while pushing LH and FSH above normal; the gel.
Both enclomiphene doses raised total testosterone, LH and FSH and kept sperm concentration in the normal range, while testosterone gel raised testosterone but lowered LH and FSH and markedly reduced sperm counts. The.
The 2026 statement recommends specialist-only, research-framework use because the drug is unlicensed in the UK and the evidence comes from small, short studies. It summarizes a retrospective comparison in which 30% of.
This 2025 page is a consumer-facing evidence summary rather than a protocol. It states that no FDA-approved prescribing information exists, that the drug is available only off-label through compounding, and that any.
This is a vendor page, not a protocol. The capsule strength matches the lower trial dose, and the published certificates show lot-to-lot content ranging from about 5% under to 18% over label, which matters for anyone.
Study models remain visible so laboratory and animal findings are not mistaken for established human outcomes.
3 protocol rows on this page come from human trials, trial registrations, regulator labels or reviews of human data. Approval status and populations are stated per row.
2 rows record what blogs, vendor write-ups or forums describe for Enclomiphene Citrate. None has been verified against primary literature.
Sequence, synonyms and registry identifiers as recorded in PubChem, the National Library of Medicine's open chemistry database. Formula, mass and CAS number are summarized at the top of the page.
trans-Clomiphene citrate, (E)-Clomiphene citrate, Androxal, Enclomid, Clomiphene B citrate, Enclomiphene citrate (USAN), UNII J303A6U9Y6, MFCD00058322
PYTMYKVIJXPNBD-BTKVJIOYSA-N
2-[4-[(E)-2-chloro-1,2-diphenylethenyl]phenoxy]-N,N-diethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid
6 curated references, each with its journal, year and study model, plus 2 community resources reported but not linked.